Aurinia voluntarily delists from TSX effective July 30, 2021; continues on Nasdaq

Aurinia Pharmaceuticals Inc.

Delisting from Toronto Stock Exchange effective July 30, 2021; no shareholder approval required.
Nasdaq accounted for ~94% of daily trading volume over past 12 months.
Dual listing costs and administrative burden no longer justified given low TSX volume.
Common shares continue trading on Nasdaq under ticker AUPH.
Canadian brokers can trade Nasdaq-listed shares; shareholder value unaffected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.